Gene therapy trial aims to save sight in boys and men with rare retinal disease

NCT ID NCT05878860

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study tests a gene therapy called ATSN-201 in males aged 6 and older with X-linked retinoschisis, a genetic eye condition that leads to vision loss. The therapy delivers a working copy of the RS1 gene to the retina. The trial has three parts: first, finding the right dose; second, expanding to more people; and third, a randomized phase to see if it improves vision compared to no treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ATSN-201 gene therapy
What this could lead to
If successful, this could become a treatment that improves vision and slows vision loss in people with X-linked retinoschisis.
What could go wrong
This is an early-to-mid stage trial with a small number of participants. Gene therapy carries risks like inflammation or immune reactions, and it may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for X-LINKED RETINOSCHISIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Associated Retina Consultants

    NOT_YET_RECRUITING

    Phoenix, Arizona, 85020, United States

    Contact

  • Bascom Palmer Eye Institute

    RECRUITING

    Miami, Florida, 33136, United States

    Contact

  • Boston Children's Hospital

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact

  • Children's Hospital of Los Angeles

    RECRUITING

    Los Angeles, California, 90027, United States

    Contact

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact

  • Columbia University

    NOT_YET_RECRUITING

    New York, New York, 100032, United States

    Contact

  • Duke University

    NOT_YET_RECRUITING

    Durham, North Carolina, 27710, United States

    Contact

  • Flaum Eye Institute, University of Rochester

    NOT_YET_RECRUITING

    Rochester, New York, 14642, United States

    Contact

  • Massachusetts Eye and Ear

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact

  • Mayo Clinic

    NOT_YET_RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact

  • Moran Eye Center

    NOT_YET_RECRUITING

    Salt Lake City, Utah, 84132, United States

    Contact

  • Oregon Health Sciences University

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact

  • Retina Foundation of the Southwest

    NOT_YET_RECRUITING

    Dallas, Texas, 75231, United States

    Contact

  • Shiley Eye Institute

    NOT_YET_RECRUITING

    La Jolla, California, 92093, United States

    Contact

  • Stanford University

    NOT_YET_RECRUITING

    Palo Alto, California, 94303, United States

    Contact

  • UC San Francisco

    NOT_YET_RECRUITING

    San Francisco, California, 94158, United States

    Contact

  • University of Michigan

    NOT_YET_RECRUITING

    Ann Arbor, Michigan, 48105, United States

    Contact

  • University of Wisconsin

    NOT_YET_RECRUITING

    Madison, Wisconsin, 53705, United States

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.